Join us at Lineage Cell Therapeutics as we support Spinal Cord Injury Day on September 5, designated by The International Spinal Cord Society - ISCOS, to raise awareness of the daily challenges faced by individuals living with spinal cord injuries. Learn more about #SCI Day: https://bit.ly/3ASQfPh #ReplaceandRestore #SpinalCordInjury #WorldSCIDay
Lineage Cell Therapeutics
Biotechnology Research
Carlsbad, CA 5,202 followers
A clinical-stage biotechnology company developing novel cell therapies for unmet medical needs.
About us
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its proprietary cell-based therapy platform and associated development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally-differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed either to replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical assets include (i) OpRegen®, a retinal pigment epithelium transplant therapy in Phase I/IIa development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase I/IIa development for the treatment of acute spinal cord injuries; and (iii) VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells currently in Phase I development for the treatment of non-small cell lung cancer. For more information, please visit www.lineagecell.com.
- Website
-
http://www.lineagecell.com
External link for Lineage Cell Therapeutics
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Carlsbad, CA
- Type
- Public Company
- Founded
- 1990
Locations
-
Primary
2173 Salk Avenue
Suite 200
Carlsbad, CA 92008, US
-
1010 Atlantic Avenue
Suite 102
Alameda, CA 94501, US
Employees at Lineage Cell Therapeutics
Updates
-
California Institute for Regenerative Medicine (CIRM)’s blog highlights the resilience and achievements of Jake Javier, a #SpinalCordInjury #ClinicalTrial pioneer who received Lineage Cell Therapeutics' OPC1 #CellTransplant. Learn more about his inspiring story: https://bit.ly/3SXf0Ad Watch Jake’s journey: https://bit.ly/3YLU1nA #ReplaceAndRestore #CIRMTraineeConference #CIRM-funded
-
Join Brian Culley, CEO of Lineage Cell Therapeutics, as he presents at the H.C. Wainwright & Co., LLC’s 4th Annual Ophthalmology Virtual Conference on August 15, 2024. Webcast available after 7 am ET: https://bit.ly/3YDGQ8b #ReplaceAndRestore #Biotech #Ophthalmology
-
Today Lineage Cell Therapeutics reported second quarter 2024 financial and operating results and will host a conference call at 4:30 pm ET / 1:30 pm PT. Learn more: https://bit.ly/4dxs6vG #ReplaceAndRestore
-
Lineage Cell Therapeutics will report second quarter 2024 financial results on Thursday, August 8, 2024, and host a conference call at 4:30 pm ET / 1:30 pm PT to provide a business update. Learn more: https://bit.ly/4cgZiGY #ReplaceAndRestore
-
Lineage Cell Therapeutics has been added as a member of the broad-market Russell 3000® Index, effective July 1st, as part of the 2024 Russell indexes reconstitution. The annual reconstitution captures the 4,000 largest US stocks as of April 30, 2024, ranking them by total market capitalization. For more: https://lnkd.in/e-W2JN-F #ReplaceandRestore #RussellRecon FTSE Russell, An LSEG Business
-
Lineage Cell Therapeutics’ CEO Brian Culley is interviewed by Brian Orelli from BiotechTV on the idea for the SCI Investor Symposium and our approach to spinal cord injury treatments. Watch the interview here: https://bit.ly/3W3xvEV #ReplaceandRestore #SCI #SpinalCordInjury
-
And that’s a wrap! Thanks so much to all the attendees, sponsors, and presenters, who made #SCISymposium a great success! Keep an eye out for more information on replays from the Symposium in the coming weeks! Lineage Cell Therapeutics California Institute for Regenerative Medicine (CIRM) Christopher & Dana Reeve Foundation #SCI #SpinalCordInjury
-
An insightful session from Tari Suprapto, Ph.D., of Novo Nordisk, Ilan Zipkin, Ph.D., of Supercede Therapeutics & Breakout Ventures, and moderator Liz Meeks of Leerink Partners on the investors’ perspective on #SCI. Lineage Cell Therapeutics, California Institute for Regenerative Medicine (CIRM), Christopher & Dana Reeve Foundation #SpinalCordInjury #CollaboratetoInnovate
-
Exciting updates were presented from Neuralink, Lineage Cell Therapeutics, AbbVie, ONWARD Medical, NervGen Pharma Corp., & Kringle Pharma during the Clinical #SCI session, moderated by Joseph Pantginis, Ph.D. of H.C. Wainwright & Co., LLC. Learn more: https://bit.ly/3mzDtOX California Institute for Regenerative Medicine (CIRM), Christopher & Dana Reeve Foundation #SCI #SpinalCordInjury #CollaboratetoInnovate